| Year |
Citation |
Score |
| 2024 |
Eastwood SM, Meyer MR, Kirmess KM, Wente-Roth TL, Irvin F, Holubasch MS, Verghese PB, West T, Braunstein JB, Yarasheski KE, Contois JH. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics (Basel, Switzerland). 14. PMID 39202226 DOI: 10.3390/diagnostics14161739 |
0.646 |
|
| 2024 |
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. Jama. PMID 39068545 DOI: 10.1001/jama.2024.13855 |
0.593 |
|
| 2024 |
Brier MR, Schindler SE, Salter A, Perantie D, Shelley N, Judge B, Keefe S, Kirmess KM, Verghese PB, Yarasheski KE, Venkatesh V, Raji CA, Gordon BA, Bateman RJ, Morris JC, et al. Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients. Annals of Neurology. PMID 38963256 DOI: 10.1002/ana.27027 |
0.581 |
|
| 2024 |
Feldman HH, Luchsinger JA, Léger GC, Taylor C, Jacobs DM, Salmon DP, Edland SD, Messer K, Revta C, Flowers SA, Jones KS, Koulman A, Yarasheski KE, Verghese PB, Venkatesh V, et al. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam). Plos One. 19: e0302998. PMID 38809849 DOI: 10.1371/journal.pone.0302998 |
0.313 |
|
| 2024 |
Molina-Henry DP, Raman R, Liu A, Langford O, Johnson K, Shum LK, Glover CM, Dhadda S, Irizarry M, Jimenez-Maggiora G, Braunstein JB, Yarasheski K, Venkatesh V, West T, Verghese PB, et al. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38629508 DOI: 10.1002/alz.13803 |
0.62 |
|
| 2024 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 19: 27. PMID 38519970 DOI: 10.1186/s13024-024-00716-w |
0.53 |
|
| 2024 |
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, ... ... Verghese PB, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38491912 DOI: 10.1002/alz.13764 |
0.749 |
|
| 2023 |
Cook JD, Malik A, Plante DT, Norton D, Koscik RL, Du L, Bendlin BB, Kirmess KM, Holubasch MS, Meyer MR, Venkatesh V, West T, Verghese PB, Yarasheski KE, Thomas KV, et al. Associations of Sleep Duration and Daytime Sleepiness with Plasma Amyloid Beta and Cognitive Performance in Cognitively Unimpaired, Middle-Aged and Older Adult African Americans. Sleep. PMID 38011629 DOI: 10.1093/sleep/zsad302 |
0.5 |
|
| 2023 |
Fischer B, Van Hulle CA, Langhough R, Norton D, Zuelsdorff M, Gooding DC, Wyman MF, Johnson A, Lambrou N, James T, Bouges S, Carter FP, Salazar H, Kirmess K, Holubasch M, ... ... Verghese P, et al. Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA-FAIM cohort. Alzheimer's & Dementia (New York, N. Y.). 9: e12414. PMID 37752907 DOI: 10.1002/trc2.12414 |
0.591 |
|
| 2023 |
Fogelman I, West T, Braunstein JB, Verghese PB, Kirmess KM, Meyer MR, Contois JH, Shobin E, Ferber KL, Gagnon J, Rubel CE, Graham D, Bateman RJ, Holtzman DM, Huang S, et al. Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Annals of Clinical and Translational Neurology. PMID 36975407 DOI: 10.1002/acn3.51763 |
0.759 |
|
| 2022 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 17: 71. PMID 36329501 DOI: 10.1186/s13024-022-00573-5 |
0.53 |
|
| 2022 |
Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P, West T, Meyer MR, Kirmess KM, Fagan AM, Xiong C, Holtzman D, Morris JC, Bateman RJ, Schindler SE. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Annals of Clinical and Translational Neurology. PMID 36183195 DOI: 10.1002/acn3.51670 |
0.699 |
|
| 2022 |
Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, ... ... Verghese PB, et al. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. Jama Network Open. 5: e228392. PMID 35446396 DOI: 10.1001/jamanetworkopen.2022.8392 |
0.739 |
|
| 2021 |
Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, Harpstrite SE, Verghese PB, West T, Fogelman I, Braunstein JB, Yarasheski KE, Contois JH. The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis. Clinica Chimica Acta; International Journal of Clinical Chemistry. PMID 34015303 DOI: 10.1016/j.cca.2021.05.011 |
0.647 |
|
| 2021 |
West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration. 16: 30. PMID 33933117 DOI: 10.1186/s13024-021-00451-6 |
0.754 |
|
| 2019 |
Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high density lipoprotein-like particles is protected from aggregation. Febs Letters. PMID 31058310 DOI: 10.1002/1873-3468.13428 |
0.489 |
|
| 2019 |
Yarasheski KE, West T, Verghese PB, Hu Y, Kirmess K, Meyer M, Smith E, Harpstrite S, Holubasch M, Knapik S, Harlan A, Fogelman I, Braunstein JB. F4-01-01: PLASMA TEST FOR AMYLOID RISK SCREENING: THE C2
N SPONSORED PARIS ADD-ON STUDY TO IDEAS. Alzheimer's & Dementia. 15: P1216-P1216. DOI: 10.1016/J.Jalz.2019.06.4713 |
0.544 |
|
| 2018 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 13: 57. PMID 30340601 DOI: 10.1186/S13024-018-0286-0 |
0.672 |
|
| 2017 |
West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. The Journal of Prevention of Alzheimer's Disease. 4: 236-241. PMID 29181488 DOI: 10.14283/jpad.2017.36 |
0.622 |
|
| 2017 |
Liu S, Park S, Allington G, Prelli F, Sun Y, Martá-Ariza M, Scholtzova H, Biswas G, Brown B, Verghese PB, Mehta PD, Kwon YU, Wisniewski T. Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline. Scientific Reports. 7: 8009. PMID 28808293 DOI: 10.1038/S41598-017-08604-8 |
0.554 |
|
| 2017 |
Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine. 9. PMID 28424326 DOI: 10.1126/Scitranslmed.Aal2029 |
0.69 |
|
| 2017 |
Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Toxicology and Applied Pharmacology. PMID 28315356 DOI: 10.1016/J.Taap.2017.03.014 |
0.72 |
|
| 2017 |
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R. Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 12: 3. PMID 28081701 DOI: 10.1186/s13024-016-0147-7 |
0.415 |
|
| 2017 |
Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I, Roberson ED, Hu H, Verghese PB, Bateman RJ, Florian H, Wang D, Ryman D, Gault L, Goss S, et al. [O2-17-01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P599-P600. DOI: 10.1016/J.Jalz.2017.07.241 |
0.616 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimer's & Dementia (New York, N. Y.). 2: 110-120. PMID 29067298 DOI: 10.1016/J.Trci.2016.06.001 |
0.73 |
|
| 2016 |
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 11: 74. PMID 27931262 DOI: 10.1186/S13024-016-0138-8 |
0.552 |
|
| 2016 |
Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America. PMID 27559087 DOI: 10.1073/Pnas.1609896113 |
0.59 |
|
| 2016 |
Reynolds MR, Singh I, Azad TD, Holmes BB, Verghese PB, Dietrich HH, Diamond M, Bu G, Han BH, Zipfel GJ. Heparan sulfate proteoglycans mediate Aβ-induced oxidative stress and hypercontractility in cultured vascular smooth muscle cells. Molecular Neurodegeneration. 11: 9. PMID 26801396 DOI: 10.1186/S13024-016-0073-8 |
0.424 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 110-120. DOI: 10.1016/j.trci.2016.06.001 |
0.733 |
|
| 2015 |
Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, Ramírez CM, Verghese PB, Ihara M, Hoe HS, Esau C, Fernández-Hernando C, Holtzman DM, Cirrito JR, Ono K, et al. microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 14717-26. PMID 26538644 DOI: 10.1523/Jneurosci.2053-15.2015 |
0.785 |
|
| 2014 |
Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry. 53: 6323-31. PMID 25207746 DOI: 10.1021/Bi5008172 |
0.629 |
|
| 2013 |
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America. 110: E1807-16. PMID 23620513 DOI: 10.1073/Pnas.1220484110 |
0.753 |
|
| 2013 |
Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration. 8: 13. PMID 23601557 DOI: 10.1186/1750-1326-8-13 |
0.774 |
|
| 2012 |
Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. The Journal of Experimental Medicine. 209: 2149-56. PMID 23129750 DOI: 10.1084/Jem.20121274 |
0.787 |
|
| 2012 |
Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America. 109: 15502-7. PMID 22927427 DOI: 10.1073/Pnas.1206446109 |
0.778 |
|
| 2012 |
Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. The Journal of Biological Chemistry. 287: 13959-71. PMID 22383525 DOI: 10.1074/Jbc.M111.288746 |
0.782 |
|
| 2011 |
Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, Wroge CM, Mennerick S, Neil JJ, Milbrandt J, Holtzman DM. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proceedings of the National Academy of Sciences of the United States of America. 108: 19054-9. PMID 22058226 DOI: 10.1073/Pnas.1107325108 |
0.45 |
|
| 2011 |
Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7049-59. PMID 21562267 DOI: 10.1523/Jneurosci.6546-10.2011 |
0.635 |
|
| 2011 |
Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet. Neurology. 10: 241-52. PMID 21349439 DOI: 10.1016/S1474-4422(10)70325-2 |
0.745 |
|
| 2011 |
Howard AD, Verghese PB, Arrese EL, Soulages JL. The β-subunit of ATP synthase is involved in cellular uptake and resecretion of apoA-I but does not control apoA-I-induced lipid efflux in adipocytes. Molecular and Cellular Biochemistry. 348: 155-64. PMID 21069432 DOI: 10.1007/S11010-010-0650-Z |
0.341 |
|
| 2011 |
Castellano J, Verghese P, Stewart F, DeMattos R, Holtzman D. P2-221: Synthetic human apoE particles differentially regulate brain interstitial amyloid-beta levels Alzheimer's & Dementia. 7: S383-S383. DOI: 10.1016/J.Jalz.2011.05.1103 |
0.654 |
|
| 2010 |
Howard AD, Verghese PB, Arrese EL, Soulages JL. Characterization of apoA-I-dependent lipid efflux from adipocytes and role of ABCA1. Molecular and Cellular Biochemistry. 343: 115-24. PMID 20535530 DOI: 10.1007/S11010-010-0505-7 |
0.327 |
|
| 2008 |
Verghese PB, Arrese EL, Howard AD, Soulages JL. Brefeldin A inhibits cholesterol efflux without affecting the rate of cellular uptake and re-secretion of apolipoprotein A-I in adipocytes. Archives of Biochemistry and Biophysics. 478: 161-6. PMID 18708026 DOI: 10.1016/J.Abb.2008.07.025 |
0.336 |
|
| 2007 |
Verghese PB, Arrese EL, Soulages JL. Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Molecular and Cellular Biochemistry. 302: 241-8. PMID 17390217 DOI: 10.1007/S11010-007-9447-0 |
0.324 |
|
| Show low-probability matches. |